Gee, Melaney K <br/><br/>
Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys.  [electronic resource] 

 -  Metabolism: clinical and experimental  Sep 2004 
 - 1121-5 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0026-0495 
<br/><br/><label>Standard No.: </label>10.1016/j.metabol.2004.03.014  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Biomarkers<br/>Body Weight--physiology<br/>C-Reactive Protein--metabolism<br/>Diabetes Mellitus, Type 2--complications<br/>Female<br/>Glucose Tolerance Test<br/>Hyperlipidemias--complications<br/>Hypoglycemic Agents--therapeutic use<br/>Insulin--metabolism<br/>Lipids--blood<br/>Macaca fascicularis<br/>Male<br/>Receptors, Cytoplasmic and Nuclear--agonists<br/>Rosiglitazone<br/>Sex Characteristics<br/>Thiazolidinediones--therapeutic use<br/>Transcription Factors--agonists<br/>Triglycerides--blood<br/>Tumor Necrosis Factor-alpha--metabolism